MedTrace Logo

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT04369183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-12-01

No results posted yet for this study

Summary

Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far. In the light of these studies, corticosteroids and calcineurin inhibitors have been the treatment of choice and mycophenolic acid derivatives have been seen as a second line agent. However, treatment options in refractory or relapsed cases are still under debate. Recently, rituximab has become an alternative in those patients. Therefore, a study based on registry data was conducted to evaluate the efficacy and safety of rituximab in adult patients suffering from a relapsed or refractory primary FSGS or MCD.

Conditions

  • Focal Segmental Glomerulosclerosis
  • Minimal Change Disease

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Halil Yazici, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

  • Safak Mirioglu, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-08-31
Completion
2020-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04369183 on ClinicalTrials.gov